Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Balena

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Calcified Tissue International|April 25, 2000
Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up studyI Fogelman, R J Herd, G M Blake, et al.
Bone|January 1, 1991
Hypophosphatemic rickets with hypocalciuria following long-term treatment with aluminum-containing antacidJ Foldes, R Balena, A Ho, et al.
Connective Tissue Research|January 1, 1995
The role of prostaglandins in bone formationS I Harada, R Balena, G A Rodan, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 26, 2009
Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetesC Kapitza, T Heise, P Birman, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 12, 2010
Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled studyR Ratner, M Nauck, C Kapitza, et al.
Histochemistry|April 1, 1993
The effects of three different demineralization agents on osteopontin localization in adult rat bone using immunohistochemistryJ D Frank, R Balena, P Masarachia, et al.
The American Journal of Medicine|August 1, 1997
The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled studyR J Herd, R Balena, G M Blake, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled studyP D Delmas, R Balena, E Confravreux, et al.
The Journal of Clinical Endocrinology and Metabolism|September 1, 1997
Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up)P J Meunier, E Confavreux, I Tupinon, et al.
Calcified Tissue International|October 1, 1993
The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in ratsM Yamamoto, A Markatos, J G Seedor, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Calcified Tissue International|April 25, 2000
Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up studyI Fogelman, R J Herd, G M Blake, et al.
Bone|January 1, 1991
Hypophosphatemic rickets with hypocalciuria following long-term treatment with aluminum-containing antacidJ Foldes, R Balena, A Ho, et al.
Connective Tissue Research|January 1, 1995
The role of prostaglandins in bone formationS I Harada, R Balena, G A Rodan, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 26, 2009
Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetesC Kapitza, T Heise, P Birman, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 12, 2010
Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled studyR Ratner, M Nauck, C Kapitza, et al.
Histochemistry|April 1, 1993
The effects of three different demineralization agents on osteopontin localization in adult rat bone using immunohistochemistryJ D Frank, R Balena, P Masarachia, et al.
The American Journal of Medicine|August 1, 1997
The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled studyR J Herd, R Balena, G M Blake, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled studyP D Delmas, R Balena, E Confravreux, et al.
The Journal of Clinical Endocrinology and Metabolism|September 1, 1997
Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up)P J Meunier, E Confavreux, I Tupinon, et al.
Calcified Tissue International|October 1, 1993
The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in ratsM Yamamoto, A Markatos, J G Seedor, et al.
Pageof 4